{"id":"bimatoprost-0-03-solution","safety":{"commonSideEffects":[{"rate":"10-50","effect":"Increased iris pigmentation"},{"rate":"10-50","effect":"Eyelash growth (hypertrichosis)"},{"rate":"20-40","effect":"Conjunctival hyperemia"},{"rate":"10-30","effect":"Eye irritation/discomfort"},{"rate":"5-15","effect":"Darkening of periocular skin"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bimatoprost mimics the action of prostaglandin F by activating F-prostanoid receptors in the eye. This activation enhances drainage of aqueous humor through the uveoscleral (unconventional) pathway, leading to decreased intraocular pressure. The drug is selective for prostaglandin F receptors and does not significantly activate other prostaglandin receptor subtypes.","oneSentence":"Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:03.712Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT06761313","phase":"PHASE4","title":"Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2021-03-01","conditions":"Glaucoma, Quality of Life (QOL)","enrollment":40},{"nctId":"NCT05600673","phase":"PHASE1, PHASE2","title":"Combined CO2 Fractional Laser With Bimatoprost 0.03% Treatment of Alopecia Areata","status":"COMPLETED","sponsor":"Ahmed Hassan Nouh MD","startDate":"2019-01-01","conditions":"Alopecia Areata","enrollment":30},{"nctId":"NCT03284853","phase":"PHASE3","title":"Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2017-09-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":436},{"nctId":"NCT02830776","phase":"EARLY_PHASE1","title":"Topical Bimatoprost for Chemical Blepharoplasty","status":"COMPLETED","sponsor":"Tulane University","startDate":"2016-11","conditions":"Dermatochalasis","enrollment":15},{"nctId":"NCT02017327","phase":"PHASE4","title":"Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2013-12","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":379},{"nctId":"NCT01157364","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-09-23","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":109},{"nctId":"NCT01391273","phase":"PHASE3","title":"Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-07-01","conditions":"Eyelash Hypotrichosis","enrollment":173},{"nctId":"NCT01391286","phase":"PHASE3","title":"Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-07-01","conditions":"Eyelash Hypotrichosis","enrollment":36},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT03419715","phase":"PHASE2","title":"Topical Bimatoprost in the Treatment of Migraine","status":"UNKNOWN","sponsor":"Manistee Partners","startDate":"2018-01-05","conditions":"Migraine Disorders, Headache Disorders","enrollment":70},{"nctId":"NCT00440011","phase":"PHASE4","title":"Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%","status":"COMPLETED","sponsor":"Allergan","startDate":"2006-08","conditions":"Glaucoma, Ocular Hypertension","enrollment":266},{"nctId":"NCT01170884","phase":"PHASE4","title":"Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-12","conditions":"Glaucoma, Ocular Hypertension","enrollment":121},{"nctId":"NCT00539526","phase":"PHASE4","title":"Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-09","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":106},{"nctId":"NCT01243567","phase":"PHASE4","title":"Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06-01","conditions":"Glaucoma, Open-Angle","enrollment":81},{"nctId":"NCT01068964","phase":"NA","title":"Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-02-01","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":235},{"nctId":"NCT01099774","phase":"PHASE3","title":"Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-05-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":597},{"nctId":"NCT01023841","phase":"PHASE4","title":"Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06-01","conditions":"Eyelash Hypotrichosis, Alopecia Areata","enrollment":71},{"nctId":"NCT02176356","phase":"PHASE4","title":"Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-06-30","conditions":"Facial Rhytides, Crow's Feet Lines, Glabellar Lines","enrollment":116},{"nctId":"NCT01298700","phase":"PHASE4","title":"Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-05-31","conditions":"Glaucoma, Ocular Hypertension","enrollment":806},{"nctId":"NCT02505776","phase":"","title":"Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-12-08","conditions":"Eyelash Hypotrichosis","enrollment":1699},{"nctId":"NCT02571712","phase":"PHASE4","title":"Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2015-11-10","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":750},{"nctId":"NCT03487042","phase":"PHASE4","title":"Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-05","conditions":"Generalized Vitiligo","enrollment":40},{"nctId":"NCT01230736","phase":"PHASE4","title":"Safety and Efficacy of Changing to DuoTrav From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-10","conditions":"Glaucoma","enrollment":105},{"nctId":"NCT02059655","phase":"PHASE4","title":"Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)","status":"COMPLETED","sponsor":"Cardiff University","startDate":"2014-11","conditions":"Graves' Ophthalmopathy","enrollment":31},{"nctId":"NCT00705757","phase":"PHASE4","title":"The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye","status":"COMPLETED","sponsor":"Summa Health System","startDate":"2008-03","conditions":"Glaucoma, Application Site Pigmentation Changes","enrollment":89},{"nctId":"NCT01016691","phase":"PHASE2","title":"Safety and Efficacy of a Drug Delivery System in Glaucoma","status":"COMPLETED","sponsor":"Vistakon Pharmaceuticals","startDate":"2009-10","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":47},{"nctId":"NCT01698554","phase":"PHASE3","title":"Bimatoprost in the Treatment of Eyelash Hypotrichosis","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-11","conditions":"Idiopathic Eyelash Hypotrichosis","enrollment":464},{"nctId":"NCT01891487","phase":"PHASE4","title":"Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning Eyebrows","status":"COMPLETED","sponsor":"ATS Clinical Research","startDate":"2013-05","conditions":"Hypotrichosis","enrollment":33},{"nctId":"NCT02170662","phase":"PHASE2","title":"Topical Bimatoprost Effect on Androgen Dependent Hair Follicles","status":"COMPLETED","sponsor":"Duke University","startDate":"2009-11","conditions":"Male Pattern Hair Loss, Androgenetic Alopecia","enrollment":33},{"nctId":"NCT01110499","phase":"PHASE2","title":"Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06","conditions":"Ocular Hypertension, Primary Open-Angle Glaucoma","enrollment":163},{"nctId":"NCT01200251","phase":"PHASE3","title":"Study of Bimatoprost Gel on Eyelash Growth","status":"COMPLETED","sponsor":"Duke University","startDate":"2007-02","conditions":"Madarosis, Hypotrichosis","enrollment":20},{"nctId":"NCT01327599","phase":"PHASE4","title":"Efficacy of Changing to DUOTRAV® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-08","conditions":"Open-Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma","enrollment":60},{"nctId":"NCT01291108","phase":"PHASE2","title":"Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-04","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":125},{"nctId":"NCT00693420","phase":"PHASE3","title":"Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-04","conditions":"Eyelashes","enrollment":278},{"nctId":"NCT00809848","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-02","conditions":"Ocular Hypertension, Glaucoma","enrollment":172},{"nctId":"NCT01001195","phase":"PHASE2","title":"Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-11","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":165},{"nctId":"NCT01448525","phase":"PHASE4","title":"Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-10","conditions":"Hypotrichosis","enrollment":88},{"nctId":"NCT01177098","phase":"PHASE3","title":"Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":561},{"nctId":"NCT00907426","phase":"PHASE3","title":"Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-08","conditions":"Hypotrichosis","enrollment":368},{"nctId":"NCT00958035","phase":"PHASE4","title":"Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-11","conditions":"Hypotrichosis","enrollment":89},{"nctId":"NCT01064882","phase":"PHASE2","title":"Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-03","conditions":"Eyelash Hypotrichosis","enrollment":104},{"nctId":"NCT00541242","phase":"PHASE4","title":"Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-12","conditions":"Ocular Hypertension, Glaucoma","enrollment":586},{"nctId":"NCT01202513","phase":"PHASE4","title":"Topical Bimatoprost Solution 0.03%in Stable Vitiligo","status":"WITHDRAWN","sponsor":"Gian Sagar Medical College and Hospital","startDate":"2010-08","conditions":"Vitiligo, Repigmentation","enrollment":20},{"nctId":"NCT00187577","phase":"NA","title":"Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2005-06","conditions":"Alopecia Areata","enrollment":14},{"nctId":"NCT00651859","phase":"PHASE2","title":"Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2002-11","conditions":"Glaucoma, Ocular Hypertension","enrollment":111},{"nctId":"NCT00652496","phase":"PHASE2","title":"Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":249},{"nctId":"NCT00355446","phase":"PHASE4","title":"Bioavailability of Bimatoprost Ophthalmic Solution in Human Aqueous.","status":"COMPLETED","sponsor":"Indiana University School of Medicine","startDate":"2001-07","conditions":"Cataract","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Topical treatment of skin lesions","LUMIGAN®","Latisse®","LATISSE®","Lumigan®"],"phase":"marketed","status":"active","brandName":"Bimatoprost 0.03% solution","genericName":"Bimatoprost 0.03% solution","companyName":"Ahmed Hassan Nouh MD","companyId":"ahmed-hassan-nouh-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bimatoprost 0.03% solution is a small molecule that acts as a prostaglandin F2-alpha receptor agonist. It has been studied for various conditions, including glaucoma, open-angle glaucoma, and male pattern hair loss, among others.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}